Balashiha, Moscow, Russian Federation
employee
employee
employee
employee
CSCSTI 68.41
Relevance. Acarosis in dogs (demodicosis, otodectosis, and sarcoptic mange) is one of the reasons for visiting a veterinarian; long-acting systemic acaricides with high compliance are important for controlling infestations and reducing the risk of re-infestation. Objective. To summarize the data on the therapeutic efficacy of Vepripak® (fluralaner, chewable tablet) in the treatment of demodicosis, otodectosis, and sarcoptic mange in dogs. Materials and methods. The data of a pilot clinical observation and a prospective multicenter open study (total 986 dogs, aged 6 months to 10 years) were analyzed, as well as a study of palatability (n=520). Vepripak® was administered orally once at a dose of 25…56 mg of fluralaner/kg of body weight; in the protocol – at least 2 hours after the last feeding. The efficacy in acarosis was assessed by the dynamics of clinical signs and microscopy (skin scrapings/ear secretions). Results. 100% therapeutic efficacy was observed in dogs with diagnosed acarosis. demodicosis, otodectosis, and sarcoptic mange: Demodex canis was not detected in scrapings after 14 days, Otodectes cynotis was not detected after 28 days, and clinical improvement in sarcoptic mange was observed after 2 to 4 weeks. In a multicenter study, no adverse events were reported during a 12-week period, and the voluntary consumption of the chewable form was 99.8%. Conclusion. Vepripak® demonstrated high clinical efficacy in a series of observations of major acaroses in dogs and high consumption, which may increase adherence to therapy in dermatological practice.
Vepripak®, fluralaner, demodicosis, otodectosis, sarcoptic mange, dogs, chewable tablet
1. Shagova, N.V. Effektivnost' i bezopasnost' primeneniya protivoparazitarnogo preparata Vepripak® v sravnenii s preparatom Bravekto® dlya profilaktiki i lecheniya ektoparazitozov i transmissivnyh zabolevaniy (babezioza) u sobak / N.V. Shagova, Yu.E. Bordukova, I.A. Platonova, E.V. Viktorova // Rossiyskiy veterinarnyy zhurnal. ‒ 2025. – № 1. – S. 41-48. DOI:https://doi.org/10.32416/2500–4379–2025–1–41–48.
2. Kupriyanova, L.I. Effektivnost' i bezopasnost' primeneniya protivoparazitarnogo preparata Vepripak® dlya profilaktiki i lecheniya ektoparazitozov i transmissivnyh zabolevaniy (babezioza) u sobak / L.I. Kupriyanova, N.V. Shagova, Yu.E. Bordukova, V.N. Nemesh, M.Yu. Dranicina, E.V. Viktorova, S.A. Platonova // Sovremennaya veterinarnaya medicina. – 2025. – № 6. – S. 13-20.
3. Viktorova, E.V. Klinicheskoe issledovanie vkusovoy privlekatel'nosti zhevatel'noy tabletki preparata «Vepripak» u sobak/ E.V. Viktorova, N.V. Shagova, S.A. Platonova // Sovremennaya veterinarnaya medicina. – 2025. – № 5. – S. 26-28.
4. Fedulova, L. V. Issledovanie bioekvivalentnosti veterinarnyh preparatov na osnove fluralanera: Vepripak® i Bravekto® / L.V. Fedulova, E.V. Viktorova, S.A. Platonova // Rossiyskiy veterinarnyy zhurnal. – 2025. – № 4. – S. 54-59. DOI:https://doi.org/10.32416/2500–4379–2025–4–54–59.
5. Djuric, M., Efficacy of oral fluralaner for the treatment of canine generalized demodicosis: a molecular-level confirmation / M. Djuric, N. Milcic Matic, Dar. Davitkov, U. Glavinic, Daj. Davitkov, B. Vejnovic, Z. Stanimirovic // Parasit Vectors. ‒ 2019 May. ‒ Vol. 28. No.12(1). ‒ pp. 270. DOI:https://doi.org/10.1186/s13071-019-3521-9.
6. Chiummo, R. Efficacy of orally and topically administered fluralaner (Bravecto®) for treatment of client-owned dogs with sarcoptic mange under field conditions / R. Chiummo, I. Petersen, C. Plehn, E. Zschiesche, R. Roepke, E. Thomas // Parasit Vectors. ‒ 2020 Oct. ‒Vol. 17. ‒ No. 13(1). ‒ pp. 524. DOI: 10.1. ‒186/s13071-020-04395-6.
